ArmaGen’s AGT-181 Demonstrates Neurocognitive Benefit in Children with Severe MPS I

February 8, 2018

Responsive image

CALABASAS, Calif., Feb. 8, 2018 /PRNewswire/ — ArmaGen, Inc., a privately held biotechnology company focused on developing groundbreaking therapies to treat severe neurological disorders, today reported full 52-week results from a Phase 2 proof-of-concept study with AGT-181, the…

Category: Precious Metals